

Highlights of This Issue 1629

SPECIAL FEATURES

CCR Translations

- 1631 **Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?**
Joseph H. McCarty
See article, p. 1773
- 1634 **Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes**
Geoffrey R. Oxnard and Pasi A. Jänne
See article, p. 1894

CCR New Strategies

- 1637 **New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice**
Zuzana Tothova, David P. Steensma, and Benjamin L. Ebert

Molecular Pathways

- 1644 **Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer**
Jason S. Damiano and Ernesto Wasserman
- 1651 **Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment**
Roisin M. Connolly, Nguyen K. Nguyen, and Saraswati Sukumar

Review

- 1660 **Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties**
Clémentine Sarkozy and Bertrand Coiffier

HUMAN CANCER BIOLOGY

- 1670 **Expansion of CCR8⁺ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas**
Evgeniy Eruslanov, Taryn Stoffs, Wan-Ju Kim, Irina Daurkin, Scott M. Gilbert, Li-Ming Su, Johannes Vieweg, Yehia Daaka, and Sergei Kusmartsev
- 1681 **G Protein-Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor-Positive Breast Cancer Patients**
Stefan Broselid, Benxu Cheng, Martin Sjöström, Kristina Lövgren, Heather L.P. Klug-De Santiago, Mattias Belting, Karin Jirstrom, Per Malmström, Björn Olde, Pär-Ola Bendahl, Linda Hartman, Märten Fernö, and L.M. Fredrik Leeb-Lundberg
- 1693 **Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium**
Chen Chen, Carrie A. Duckworth, Qicheng Zhao, David Mark Pritchard, Jonathan M. Rhodes, and Lu-Gang Yu
- 1705 **β -1,4-Galactosyltransferase III Enhances Invasive Phenotypes Via β 1-Integrin and Predicts Poor Prognosis in Neuroblastoma**
Hsiu-Hao Chang, Chia-Hua Chen, Chih-Hsing Chou, Yung-Feng Liao, Miao-Juei Huang, Ya-Hsin Chen, Wei-Jen Wang, John Huang, Ji-Shiang Hung, Wan-Ling Ho, Yung-Ming Jeng, Mei-Ieng Che, Hsin-yu Lee, Meng-Yao Lu, Yung-Li Yang, Shiann-Tarng Jou, Dong-Tsamn Lin, Kai-Hsin Lin, Wen-Ming Hsu, and Min-Chuan Huang

CANCER THERAPY: PRECLINICAL

- 1717 **The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells *In Vitro* and *In Vivo***
Ning Zhou, Kamini Singh, Maria C. Mir, Yvonne Parker, Daniel Lindner, Robert Dreicer, Jeffrey A. Ecsedy, Zhongfa Zhang, Bin T. Teh, Alexandru Almasan, and Donna E. Hansel

1729 **Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis**
Anna Kalota, Grace R. Jeschke, Martin Carroll, and Elizabeth O. Hexner

1740 **Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent**
Emilia M. Pinto, Christopher Morton, Carlos Rodriguez-Galindo, Lisa McGregor, Andrew M. Davidoff, Kimberly Mercer, Larisa V. Debelenko, Catherine Billups, Raul C. Ribeiro, and Gerard P. Zambetti

1748 **Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma**
Zhixiang Cheng, Yuanying Gong, Yufang Ma, Kaihua Lu, Xiang Lu, Larry A. Pierce, Reid C. Thompson, Susanne Muller, Stefan Knapp, and Jialiang Wang

1760 **Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models**
Jie Lin, Deepak Sampath, Michelle A. Nannini, Brian B. Lee, Michael Degtyarev, Jason Oeh, Heidi Savage, Zhengyu Guan, Rebecca Hong, Robert Kassees, Leslie B. Lee, Tyler Risom, Stefan Gross, Bianca M. Liederer, Hartmut Koeppen, Nicholas J. Skelton, Jeffrey J. Wallin, Marcia Belvin, Elizabeth Punnoose, Lori S. Friedman, and Kui Lin

1773 **Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance**
Arman Jahangiri, Michael De Lay, Liane M. Miller, W. Shawn Carbonell, Yu-Long Hu, Kan Lu, Maxwell W. Tom, Jesse Paquette, Taku A. Tokuyasu, Sean Tsao, Roxanne Marshall, Arie Perry, Kirsten M. Bjorgan, Myriam M. Chaumeil, Sabrina M. Ronen, Gabriele Bergers, and Manish K. Aghi
See commentary, p. 1631

1784 **The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells**
Clemens Krepler, Srinivas K. Chunduru, Molly B. Halloran, Xu He, Min Xiao, Adina Vultur, Jessie Villanueva, Yasuhiro Mitsuuuchi, Eric M. Neiman, Christopher Benetatos, Katherine L. Nathanson, Ravi K. Amaravadi, Hubert Pehamberger, Mark McKinlay, and Meenhard Herlyn

1795 **The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia**
Hernan Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, and Richard B. Lock

1806 **Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery**
Haifa Shen, Cristian Rodriguez-Aguayo, Rong Xu, Vianey Gonzalez-Villasana, Junhua Mai, Yi Huang, Guodong Zhang, Xiaojing Guo, Litao Bai, Guoting Qin, Xiaoyong Deng, Qingpo Li, Donald R. Erm, Burcu Aslan, Xuewu Liu, Jason Sakamoto, Arturo Chavez-Reyes, Hee-Dong Han, Anil K. Sood, Mauro Ferrari, and Gabriel Lopez-Berestein

IMAGING, DIAGNOSIS, PROGNOSIS

1816 **LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma**
Jacky T. Yeung, Ronald L. Hamilton, Koji Ohnishi, Maki Ikeura, Douglas M. Potter, Marina N. Nikiforova, Soldano Ferrone, Regina I. Jakacki, Ian F. Pollack, and Hideho Okada

1827 **Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C**
Yuji Hodo, Masao Honda, Akihiro Tanaka, Yoshimoto Nomura, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Akito Sakai, Motoko Sasaki, Yasuni Nakanuma, Mitsuhiko Moriyama, and Shuichi Kaneko

CANCER THERAPY: CLINICAL

1838 **Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia**
Ivana Gojo, Ming Tan, Hong-Bin Fang, Mariola Sadowska, Rena Lapidus, Maria R. Baer, France Carrier, Jan H. Beumer, Bean N. Anyang, Rakesh K. Srivastava, Igor Espinoza-Delgado, and Douglas D. Ross

1852 **First-in-Human Phase 0 Trial of Oral 5-Iodo-2-Pyrimidinone-2'-Deoxyribose in Patients with Advanced Malignancies**

Shivaani Kummar, Larry Anderson, Kimberly Hill, Eva Majerova, Deborah Allen, Yvonne Horneffer, S. Percy Ivy, Larry Rubinstein, Pamela Harris, James H. Doroshow, and Jerry M. Collins

1858 **Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients**

Raghvendra M. Srivastava, Steve C. Lee, Pedro A. Andrade Filho, Christopher A. Lord, Hyun-Bae Jie, H. Carter Davidson, Andrés López-Albaitero, Sandra P. Gibson, William E. Gooding, Soldano Ferrone, and Robert L. Ferris

1873 **A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2**

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmiecik, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, and Steven Grant

1884 **Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004**

George Somlo, Francesco Atzori, Lewis C. Strauss, William J. Geese, Jennifer M. Specht, William J. Gradishar, Alissa Rybicki, Oumar Sy, Linda T. Vahdat, and Javier Cortes

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

1894 **DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy**

Paul Yeh, Heidi Chen, Jenny Andrews, Riyadh Naser, William Pao, and Leora Horn
See commentary, p. 1634

1902 **Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer**

Marc Peeters, Kelly S. Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean-Luc Van Laethem, Thierry André, Jeffrey Wizezorek, David Reese, and Scott D. Patterson

CORRECTIONS

1913 **Correction: Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells**

1914 **Correction: Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors**


AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Aurora kinase A plays a key role in regulation of the mitotic spindle checkpoint, and Aurora kinase A inhibitors are currently under development as targeted anticancer agents. In this figure, human bladder carcinoma-derived T24 cells were treated with the Aurora kinase A inhibitor MLN8237 (Millennium Pharmaceuticals), and immunofluorescently stained for tubulin (green), CENPA (red), and DAPI (blue). These treated cells show marked aneuploidy as a result of mitotic failure. For details, see the article by Zhou and colleagues on page 1717 of this issue.



Clinical Cancer Research

19 (7)

Clin Cancer Res 2013;19:1629-1914.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/19/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/19/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.